



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Luspatercept

Cat. No.:	HY-P99720
CAS No.:	1373715-00-4
Target:	TGF-beta/Smad
Pathway:	Stem Cell/Wnt; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia ^[1] .								
In Vitro	Luspatercept (0.1-1000 ng/mL) inhibits Smad2 and Smad 3 signaling induced by GDF11 and GDF8 in A204 cells ^[1] . Luspatercept binds with GDF11, GDF8, activin B, BMP10 and BMP6 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>Luspatercept (0.1-60 mg/kg, s.c.; 10 mg/kg, i.v.; twice weekly for 8 weeks) increases red blood cell (RBC) count, hemoglobin levels and hematocrit in mice, rats and monkeys^[1].</p> <p>Luspatercept (10 mg/kg; s.c., once) reduces erythroid burst forming units (BFU-Es) and erythroid colony-forming units (CFU-Es) from bone marrow and spleen of C57BL/6 mice^[1].</p> <p>Luspatercept (10 mg/kg; i.p., once) inhibits Smad2/3 phosphorylation in mouse spleen^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6 mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 0.3, 1, 3 and 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection and intravenous injection; 0.1-10 mg/kg (C57BL/6 mice, s.c.), 6-60 mg/kg (Sprague Dawley rats, s.c.), 0.4-30 mg/kg (cynomolgus monkeys, s.c.), 10 mg/kg, (cynomolgus monkeys, i.v.); twice weekly for 8 weeks</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently increased the level of RBC, hemoglobin and hematocrit in mice, rats and monkeys.</td> </tr> </table>	Animal Model:	C57BL/6 mice ^[1]	Dosage:	0.1, 0.3, 1, 3 and 10 mg/kg	Administration:	Subcutaneous injection and intravenous injection; 0.1-10 mg/kg (C57BL/6 mice, s.c.), 6-60 mg/kg (Sprague Dawley rats, s.c.), 0.4-30 mg/kg (cynomolgus monkeys, s.c.), 10 mg/kg, (cynomolgus monkeys, i.v.); twice weekly for 8 weeks	Result:	Dose-dependently increased the level of RBC, hemoglobin and hematocrit in mice, rats and monkeys.
Animal Model:	C57BL/6 mice ^[1]								
Dosage:	0.1, 0.3, 1, 3 and 10 mg/kg								
Administration:	Subcutaneous injection and intravenous injection; 0.1-10 mg/kg (C57BL/6 mice, s.c.), 6-60 mg/kg (Sprague Dawley rats, s.c.), 0.4-30 mg/kg (cynomolgus monkeys, s.c.), 10 mg/kg, (cynomolgus monkeys, i.v.); twice weekly for 8 weeks								
Result:	Dose-dependently increased the level of RBC, hemoglobin and hematocrit in mice, rats and monkeys.								

REFERENCES

[1]. Suragani RN, et al. Transforming growth factor- β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014 Apr;20(4):408-14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA